Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K J Mason

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The British Journal of Dermatology|November 16, 2018
Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapyZ Z N Yiu, C Sorbe, M Lunt, et al.
The British Journal of Dermatology|August 30, 2018
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort studyR B Warren, A Marsden, B Tomenson, et al.
The British Journal of Dermatology|March 2, 2019
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasisZ Z N Yiu, K J Mason, J N W N Barker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 16, 2021
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIRK J Mason, A D Burden, J N W N Barker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2021
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapiesK J Mason, A D Burden, J N W N Barker, et al.
The British Journal of Dermatology|May 4, 2018
Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of IrelandI Garcia-Doval, M A Descalzo, K J Mason, et al.
The British Journal of Dermatology|January 11, 2019
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic reviewK J Mason, S Williams, Z Z N Yiu, et al.
The British Journal of Dermatology|April 30, 2020
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemicS K Mahil, Z Z N Yiu, K J Mason, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2021
Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional studyS K Mahil, M Yates, Z Z N Yiu, et al.
The British Journal of Dermatology|December 28, 2020
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient surveyS K Mahil, M Yates, S M Langan, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The British Journal of Dermatology|November 16, 2018
Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapyZ Z N Yiu, C Sorbe, M Lunt, et al.
The British Journal of Dermatology|August 30, 2018
Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort studyR B Warren, A Marsden, B Tomenson, et al.
The British Journal of Dermatology|March 2, 2019
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasisZ Z N Yiu, K J Mason, J N W N Barker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 16, 2021
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIRK J Mason, A D Burden, J N W N Barker, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2021
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapiesK J Mason, A D Burden, J N W N Barker, et al.
The British Journal of Dermatology|May 4, 2018
Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of IrelandI Garcia-Doval, M A Descalzo, K J Mason, et al.
The British Journal of Dermatology|January 11, 2019
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic reviewK J Mason, S Williams, Z Z N Yiu, et al.
The British Journal of Dermatology|April 30, 2020
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemicS K Mahil, Z Z N Yiu, K J Mason, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2021
Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional studyS K Mahil, M Yates, Z Z N Yiu, et al.
The British Journal of Dermatology|December 28, 2020
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient surveyS K Mahil, M Yates, S M Langan, et al.
Pageof 2